The pharmaceutical industry will face ongoing obstacles in 2012, but it should continue to remind Congress and the public that it is “a good source of jobs and a center of American innovation,” a report in Medical Marketing & Media states. Drawing upon remarks made by Coalition Executive Director John Kamp at a recent meeting of leading members of the Coalition, the report outlines the controversies likely to evolve in 2012 and suggests that although the pharma industry remains a target for proposed cost-cutting and revenue-boosting initiatives, the focus on pharma marketing is likely to be less of a priority in the coming year. Read more.

Full Story:

Related Summaries